| Cash | 142.09K |
| Prepaid Expenses | |
| Employee Receivable | |
| Total Current Assets | 187.42K |
| Property and Equipment (net of accumulated depreciation) | |
| Other Assets | 84.87K |
| Investment in Entest | |
| Total Assets | 272.28K |
| Accounts Payable | 289.74K |
| Notes Payable | |
| Accrued Payroll | 970.59K |
| Accrued Payroll Taxes | 43.34K |
| Accrued Interest | |
| Accrued Expenses | |
| Convertible Note Payable | |
| Due to Affiliate | 1K |
| Current portion, note payable to affiliated party | |
| Total Current Liabilities | 2.35M |
| Total Liabilities | 2.45M |
| Preferred Stock ($.0001 par value) 20,000,000 shares authorized; 1,963,821 issues and outstanding as of June 30, 2011 and September 30, 2010 respectively | 207 |
| Series B Preferred Shares ($.0001 par value) 2,000,000 shares authorized; 725,409 issues and outstanding as of June 30, 2011 and September 30, 2010 | |
| Common Stock ($.0001 par value 80,000,000 shares authorized; 72,189,747 and 70,404,033 shares issued and outstanding as of June 30, 2011 and September 30 , 2010 respectively | 574.64K |
| Contributed Capital | |
| Retained Earnings (Deficit) accumulated during the development stage | -37.52M |
| Equity in Earnings (Losses) of Entest BioMedical, Inc. | |
| Deficit attributable to noncontrolling interest in subsidiary | |
| Total Stockholders' Equity (Deficit) | |
| Total Liabilities and Shareholders' Equity (Deficit) | 272.28K |